Searched for
ORAL INHALED INSULIN
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhen markets come under the kind of pressure they are experiencing these days, the bears don't see fundamentals; it is all about selling. A...
- Being tactical not an option, but a necessity: Prescription for war and volatility; 7 pharma stocks with upside potential of up to 39%In times of major geopolitical conflicts, there is no point in looking at the day-to-day movement of the Nifty and Sensex. There are some s...
- Cipla launches inhalable insulin for diabetes careCipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...
- Cipla shares in focus after receiving CDSCO nod to launch inhalation insulinCipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Cipla gets CDSCO nod to launch inhalation insulinCipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Corrections are opportunities, if you enter the right sector and stocks: 5 stocks from pharma sector with an upside potential of up to 32%At a time when the Nifty and Sensex are trading with cuts in excess of 1%, talking of buying stocks may not appear quite right. But correct...
- These 5 pharma stocks can give more than 24% returns in one yearCheck out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focu...
- 7 reasons to prioritise oral hygiene this yearWhen harmful bacteria builds up in your mouth, that can lead to a lot of health scares over time.
- Nithya Balasubramanian on why Cipla will outperform its peers and market post FY23“In trade generics, Cipla traditionally has been a market leader and I believe that in the next three-four years, trade generics will conti...
- Cipla scales up offerings, investments as it eyes global lung specialty leadershipDrugmaker Cipla said it is scaling up offerings and expanding access to medicines, inhaler devices, diagnostics, as it aspires to become th...
- Suffering from type 2 diabetes? New treatments can help control blood glucose levelOn World Diabetes Day, here's a list of new medications that will make life simpler for diabetics.
- Cipla’s inhalable insulin fails to get approval for trials on Indian patientsCipla had based its application to the panel on the bioequivalence studies with Exubra, an inhalation drug and device combination that was ...
- Novo Nordisk searches for tablet to replace insulin shotsThe company that reaped nearly 80% of its $16 billion sales from insulin products last year is hopeful for a regulatory approval for its fi...
- What does your breath tell about your bodyMajority of bad breath problems in people arise out of acid reflux. Acid reflux in longer run can cause heartburn, says Dr. Malhotra.
- The Holy Grail: How Rani Therapeutics Is packing the insulin punch in pillsScientists couldn’t crack the science because enzymes in the stomach break down and digest the proteins, which are therefore not absorbed i...
- Arvind Kejriwal has high blood sugar level, to start insulin course: Family doctorArvind Kejriwal, who has been dogged of late by health problems, was today examined by his family doctor at the Secretariat here.
- Very bullish on Glenmark: Aunali Rupani, ARM ResearchNext 5 years will see a big run up in all the pharma stocks in India especially R&D.
- First needle-free insulin soonBiotechnology company Shreya Lifesciences has entered into an in-licensing agreement with US-based Generex Biotechnology Corp to market Ora...
Load More
